Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple eruptive keratoacanthoma and immunity disorders

C Dangoisse1, K Meyvisch, M Ledoux

  • 1Clinic of Dermatology, University Hospital Saint-Pierre and Brugmann, University of Brussels, Belgium.

Dermatology (Basel, Switzerland)
|January 1, 1993
PubMed
Summary

Loratadine and ranitidine treatment led to significant regression of multiple keratoacanthoma lesions in a patient with immune disorders. Researchers hypothesize a potential role for ranitidine, an H2 antihistamine, in this observed therapeutic effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variable expressivity in Buschke-Ollendorff syndrome.

Annales de dermatologie et de venereologie·2021
Same author

Effective rescue treatment with vemurafenib of an infant with high-risk Langerhans cell histiocytosis.

Annales de dermatologie et de venereologie·2020
Same author

[Editorial].

Annales de dermatologie et de venereologie·2018
Same author

Nutrient reference value: non-communicable disease endpoints--a conference report.

European journal of nutrition·2016
Same author

[Infantile hemangioma: a new indication for propranolol? Retrospective study: a case-series of 25 infants].

Revue medicale de Bruxelles·2015
Same author

[Palmoplantar neutrophilic eccrine hidradenitis with general extension in a child in remission after acute lymphoblastic leukemia].

Annales de dermatologie et de venereologie·2014

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Keratoacanthoma (KA) are common skin tumors, often associated with immune system dysfunction.
  • Witten and Zak type KA are characterized by multiple lesions and potential links to underlying immune disorders.

Observation:

  • A 68-year-old female patient presented with multiple keratoacanthoma, Witten and Zak type.
  • The patient had concurrent immune system disorders.
  • A notable regression of the keratoacanthoma lesions was observed during treatment.

Findings:

  • The patient was treated with a combination of loratadine and ranitidine.
  • Ranitidine, an H2 antihistamine, is hypothesized to play a role in the observed lesion regression.
  • This suggests a potential therapeutic avenue for managing keratoacanthoma in immunocompromised individuals.

Related Experiment Videos

Implications:

  • The findings suggest a potential novel treatment strategy for keratoacanthoma, particularly in patients with immune deficiencies.
  • Further research is warranted to elucidate the precise mechanism by which ranitidine may influence keratoacanthoma regression.
  • This case highlights the importance of considering pharmacological interventions targeting histamine pathways in dermatological conditions linked to immune dysregulation.